ReviewJournal of clinical medicine2021
Interleukin-31 and Pruritic Skin.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 50 citations in OpenAlex.
- Chronic kidney disease-associated pruritus: a perspective on skin barrier damage.Renal failure · 2026Review
- Observational
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- Cutaneous TRPV4 Potentiates the Afferent Transmission of Electroacupuncture Stimulation.ACS omega · 2026Article
- The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis.Biomedicines · 2026Review
- Preliminary IL-1 Family Cytokine Signature for Crohn's Disease Onset in Pediatric Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2026Article
- Review
- Effects of Canine-DerivedAnimals : an open access journal from MDPI · 2026Article
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Rapid resolution of guttate psoriasis with upadacitinib: a case report.Frontiers in medicine · 2026Article
- Stress mediates the association between atopic dermatitis and sleep duration in Korean adults.Scientific reports · 2025Article
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- Evaluation of filaggrin 2 expression in dogs with atopic dermatitis before and after oclacitinib maleate administration.Veterinary dermatology · 2025Article
- The Complex Epidermal and Dermal Milieu of M2 Macrophages/IL-31/IL-31RA Network May Play a Role in Keloid Associated Pruritus.Aesthetic plastic surgery · 2025Article
- Osthole ameliorates chronic pruritus in 2,4-dichloronitrobenzene-induced atopic dermatitis by inhibiting IL-31 production.Chinese herbal medicines · 2025Article
- Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.International medical case reports journal · 2025Article
- Review
- Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.Life (Basel, Switzerland) · 2024Review
- Exploring the causal relationship between inflammatory cytokines and immunoinflammatory dermatoses: a Mendelian randomization study.Frontiers in medicine · 2024Article
- Possible Association of Interleukin-31/-31RA Signalling and Basophils with Itch in Porokeratosis.Acta dermato-venereologica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin inflammation often evokes pruritus, which is the major subjective symptom in many inflammatory skin diseases such as atopic dermatitis and prurigo nodularis. Pruritus or itch is a specific sensation found only in the skin. Recent studies have stressed the pivotal role played by interleukin-31 (IL-31) in the sensation of pruritus. IL-31 is produced by various cells including T helper 2 cells, macrophages, dendritic cells and eosinophils. IL-31 signals via a heterodimeric receptor composed of IL-31 receptor A (IL-31RA) and oncostatin M receptor β. Recent clinical trials have shown that the anti-IL-31RA antibody nemolizumab can successfully decrease pruritus in patients with atopic dermatitis and prurigo nodularis. The IL-31 pathway and pruritic skin are highlighted in this review article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.